Johnson & Johnson, a pharmaceutical company developing medicines and technologies to treat complex diseases, has updated its brand image, uniting both of its two business segments under the Johnson & Johnson brand name in the UK.
Moving forward, the Company’s two segments will be more connected to the Johnson & Johnson brand.
Janssen, the Company’s pharmaceutical segment, will be known as Johnson & Johnson Innovative Medicine, and the medical technology segment will continue to be known as Johnson & Johnson MedTech. The changes are part of a global roll out of the new Johnson & Johnson brand, which were announced in September 2023.
The transition is happening at a time when Johnson & Johnson is celebrating its 100 year operation anniversary in the UK. Johnson & Johnson has stood alongside the UK through world wars, disease outbreaks and natural disasters, proudly partnering with the NHS, healthcare leaders, clinicians and patients to develop treatments and technologies along the way.
The new Johnson & Johnson brand identity builds on the Company’s legacy, while also modernising key elements to showcase healthcare innovation in a way that is inclusive. The updated brand will be rolled out across all company materials, product packaging, and branding assets over time.
